Maravai Lifesciences Holdings, Inc. (MRVI) Stock Price & Analysis
Maravai Lifesciences Holdings, Inc. (MRVI) rose 1.19% to USD 5.1 as of June 10, 2026 at 00:42 UTC, according to Nexqual real-time market data.
MRVI last closed at USD 5.04; the session ranged USD 4.89–5.17 on volume of 3,051,422 shares. Market capitalization is $1.88B, with a 52-week range of USD 1.99–5.21 (NMS). Source: Nexqual, June 10, 2026 at 00:42 UTC.
Key Statistics (as of June 10, 2026 at 00:42 UTC)
| Price | USD 5.1 |
|---|---|
| Change | ▲ 1.19% (up) |
| Previous Close | USD 5.04 |
| Open | USD 5.07 |
| Day Range | USD 4.89 – 5.17 |
| 52-Week Range | USD 1.99 – 5.21 |
| Volume | 3,051,422 shares |
| Market Cap | $1.88B |
| Exchange | NMS |
Technical Analysis (MRVI)
Nexqual's technical model rates MRVI "BUY" based on 5 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 00:42 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 72.8 (overbought) |
| vs SMA50 | Above (USD 3.93) |
| MACD | 0.31 (positive) |
Analyst Ratings (MRVI)
Wall Street analysts rate MRVI "Buy" based on 5 analysts, with a mean price target of USD 5.7 (range USD 5–6), per Nexqual as of June 10, 2026 at 00:42 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 5.7 |
| High Target | USD 6 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 5 / 3 / 0 |
Earnings (MRVI)
| Next Earnings Date | 2026-05-07 |
|---|---|
| EPS Estimate | USD -0.04 |
| Revenue Estimate | $48.68M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.01 vs est -0.05 ▲ beat |
| 2025-12-31 | USD -0.04 vs est -0.07 ▲ beat |
| 2025-09-30 | USD -0.08 vs est -0.08 ▲ beat |
| 2025-06-30 | USD -0.08 vs est -0.07 ▼ miss |
Source: Nexqual, June 10, 2026 at 00:42 UTC.
Financials & Fundamentals (MRVI)
| Total Revenue | $204.73M |
|---|---|
| Revenue Growth (YoY) | +40.50% |
| Gross Margin | +30.12% |
| Operating Margin | +1.09% |
| Profit Margin | -51.07% |
| ROE | -40.98% |
| Debt / Equity | 85.36 |
| Current Ratio | 5.91 |
| Total Cash | $165.92M |
| Total Debt | $315.03M |
| Free Cash Flow | $-11.33M |
Source: Nexqual, June 10, 2026 at 00:42 UTC.
Financial Health Score (MRVI)
Nexqual rates Maravai Lifesciences Holdings, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:42 UTC.
| Growth | Critical — Revenue -28% YoY (annual), sharp decline |
|---|---|
| Profitability | Mixed — Gross margin 30%, operating 1% |
| Balance Sheet | Mixed — $166M cash vs $315M debt |
| Cash Flow | Weak — FCF negative: -$11M, burning cash |
| Efficiency | Critical — ROE -41%, ROA -6.6% |
Ownership (MRVI)
| Insider Ownership | +14.13% |
|---|---|
| Institutional Ownership | +88.42% |
| Shares Outstanding | 147.51M |
| Float | 102.37M |
| Short % of Float | +6.85% |
Source: Nexqual, June 10, 2026 at 00:42 UTC.
Leadership (MRVI)
Maravai Lifesciences Holdings, Inc. is led by Bernd Brust (age 58), CEO & Director, per Nexqual as of June 10, 2026 at 00:42 UTC.
| CEO & Director | Bernd Brust (age 58) |
|---|---|
| Chairman of the Board | Robert Andrew Eckert (age 63) |
| EVP & Chief Financial Officer | Rajesh J. Asorpota (age 58) |
| Senior VP & Chief Scientific Officer | Chanfeng Zhao |
| Senior Director of Investor Relations | Debra Hart |
Major Backers & Investors (MRVI)
Notable institutional backers of Maravai Lifesciences Holdings, Inc. include GTCR, LLC, Braidwell LP , 12 West Capital Management Lp, according to Nexqual as of June 10, 2026 at 00:42 UTC.
Active Investors
| Investor | Stake |
|---|---|
| GTCR, LLC | 13.66% |
| Braidwell LP | 6.94% |
| 12 West Capital Management Lp | 4.92% |
| Mackenzie Financial Corporation | 4.28% |
| Renaissance Technologies | 2.89% |
| Tejara Capital Ltd | 2.37% |
| Monaco Asset Management SAM | 2.32% |
| Morgan Stanley | 2.25% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.23% |
| Vanguard Group | 7.3% |
Source: Nexqual, June 10, 2026 at 00:42 UTC.
From Maravai Lifesciences Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America.
- It operates through two segments: TRILINK and CYGNUS.
- The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).
- This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SHC | Sotera Health Company | USD 16.53 | ▲ 5.83% |
| SEER | Seer, Inc. | USD 1.69 | ▼ 5.59% |
| CERT | Certara, Inc. | USD 5.18 | ▼ 3.54% |
| CCCC | C4 Therapeutics, Inc. | USD 3.58 | ▼ 7.01% |
| BCAB | BioAtla, Inc. | USD 3.44 | ▲ 3.3% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:42 UTC. This page is informational and not investment advice.